Comment

  • 27 March 2018

    Rituximab biosimilars: is the hype warranted?

    The biosimilars market is awash with excitement. While these copycat biologic products create competition with the originator drugs, reducing costs and increasing healthcare savings, their efficacy and safety risks should...

  • 21 March 2018

    Pfizer’s rituximab biosimilar edges closer to approval

    Pfizer’s rituximab biosimilar candidate, PF-05280586, edged closer towards approval on January 24, 2018, when the company announced positive top-line results in a Phase III trial in follicular lymphoma (FL).

  • 19 March 2018

    Digital health: a new direction for neurology

    Recent years have shown a large increase in investment towards digital health, a multifaceted segment in the industry that can combine software-based therapies into different aspects of the drug development...

Close
Close
Close

Go Top